Literature DB >> 3934058

Gigantism associated with McCune-Albright's syndrome.

H Nakagawa, A Nagasaka, T Sugiura, K Nakagawa, Y Yabe, N Nihei, M Hirooka, M Itoh, A Nakai, T Ohyama.   

Abstract

The case of a 16 year-old boy with McCune-Albright's syndrome which is rarely accompanied by gigantism was studied endocrinologically. The stimulation of growth hormone (GH) release by hypoglycemia, the decline of elevated GH by hyperglycemia and a little lower somatostatin like immunoreactivity (SLI) may support abnormalities of hypothalamic function, but the existence of pituitary microadenoma cannot be ruled out because of the paradoxical suppression of GH release by oral administration of bromocriptine (CB-154) and L-DOPA and the stimulation of GH release by intravenous administration of TRH.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934058     DOI: 10.1055/s-2007-1013594

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.

Authors:  S I Sherman; P W Ladenson
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome.

Authors:  R Abs; A Beckers; F L Van de Vyver; A De Schepper; A Stevenaert; G Hennen
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

3.  McCune-Albright syndrome. A case of primary hypogonadism obscured by hyperprolactinemic hypogonadotropic hypogonadism.

Authors:  A L Swislocki; C A Camargo; A R Hoffman
Journal:  West J Med       Date:  1990-12

Review 4.  Acromegaly and McCune-Albright syndrome.

Authors:  Sylvie Salenave; Alison M Boyce; Michael T Collins; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.